Sarbani Maitra, MD
Psychiatry · Fairfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 4 carriers
- Office
- 1
Offices
1 location
Plans that list them
21 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Maitra’s office at (707) 439-7830 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A151871 · Current
Licensed to practise in California · since 2017 · expires 2026-12-31 · American University of the Caribbean School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
2 licences
- Tennessee 55981Medical Doctor · since 2017 · expires 2027-12-31Specialty on the licence: PsychiatryLicensedNo board action on this licenceCheck it with the state
- Tennessee 755Genetic Counselors · since 2026 · expires 2027-10-31LicensedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Psychiatry
Education
- American University- Carribean · MDNETHERLANDS, ANTILLES, Netherlands Antilles · 2006Medical school
- American Univ of the Caribbean · MDNetherlands-Antiles, Netherlands, Netherlands Antilles · 2006Medical school
Residency and fellowship
- Meharry Medical College Psychiatry Residency Program, PsychiatryNashville, TN · 2013–2017
- N/ANASHVILLE, TN · 2013–2017
- Family Medicine Residency Program, Family MedicineTuscaloosa, AL · 2008–2009
- N/A, Family MedicineTUSCALOOSA, AL · 2008–2009
Original Medicare doctor bills
$5,201
Medicare paid this office $5,201 for 14 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 12 | $3,614 | $80 |
Who their Medicare patients are
14 Original Medicare patients in 2024. Average age 53 · 85 and older 0% · Also on Medicaid 100% · Health risk score 1.57. Above the middle of the specialty; the typical psychiatry clinician is at 1.35.
The office billed $69,269, Medicare allowed $7,320 and paid $5,201; for 56 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 14 | 56 | 53 | 1.57 | $69,269 | $5,201 |
| 2022 | 15 | 56 | 51 | 1.43 | $9,551 | $4,343 |
| 2021 | 39 | 156 | 57 | 1.04 | $27,160 | $11,435 |
| 2020 | 48 | 137 | 60 | 1.42 | $57,819 | $15,413 |
| 2019 | 14 | 65 | 51 | 2.07 | $17,973 | $4,318 |
| 2018 | 50 | 201 | 50 | 1.35 | $46,426 | $13,775 |
| 2017 | 22 | 73 | 53 | 1.20 | $13,667 | $4,572 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 1 service
| Short return visit (20+ min) | 14 | $3,744 | $72 |
2021: 2 services
| Return visit (30+ min) | 17 | $6,144 | $61 |
| Short return visit (20+ min) | 15 | $2,247 | $75 |
2020: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,929 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,035 | $185 |
| New patient visit (60+ min) | 11 | $2,008 | $183 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $7,549 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,770 | $163 |
| Hospital discharge day management, more than 30 minutes | 11 | $903 | $82 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $498 | $31 |
2017: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,647 | $58 |
Medicaid work
$1,814 in 2019
Medicaid paid $1,814 for 51 billed services this clinician did in 2019, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 51 | $1,814 |
| 2019 | 51 | 1 | 15 | $1,814 |
| 2018 | 174 | 3 | 20 | $74,844 |
See the largest Medicaid services in earlier years
2018
| Crisis intervention mental health services, per hour | 93 | $71,714 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 68 | $2,249 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $881 |
Drugs they prescribed that Part D paid
$704,935
Pharmacies billed $704,935 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 938) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
787 generic and 151 brand-name prescriptions · $704,935 in drug cost · 103 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Austedo Xr | 16 | $216,860 | $13,554 |
| Invega Sustenna | 60 | $194,875 | $3,248 |
| Invega Trinza | 12 | $116,843 | $9,737 |
| Abilify Maintena | 27 | $77,817 | $2,882 |
| Lybalvi | 24 | $46,286 | $1,929 |
See all 29 drugs
| Austedo Xr | 16 | $216,860 | $13,554 |
| Invega Sustenna | 60 | $194,875 | $3,248 |
| Invega Trinza | 12 | $116,843 | $9,737 |
| Abilify Maintena | 27 | $77,817 | $2,882 |
| Lybalvi | 24 | $46,286 | $1,929 |
| Clozapine | 76 | $6,023 | $79 |
| Asenapine Maleate | 11 | $2,731 | $248 |
| Fluphenazine | 15 | $1,419 | $95 |
| Olanzapine | 73 | $1,139 | $16 |
| Divalproex Sodium Er | 57 | $1,126 | $20 |
| Risperidone | 74 | $998 | $13 |
| Gabapentin | 50 | $752 | $15 |
| Prazosin | 20 | $630 | $32 |
| Aripiprazole | 18 | $542 | $30 |
| Amantadine | 15 | $462 | $31 |
| Haloperidol | 19 | $316 | $17 |
| Benztropine Mesylate | 32 | $283 | $9 |
| Trazodone | 55 | $214 | $4 |
| Sertraline | 19 | $183 | $10 |
| Divalproex | 13 | $157 | $12 |
| Topiramate | 22 | $137 | $6 |
| Fluoxetine | 25 | $130 | $5 |
| Quetiapine | 24 | $121 | $5 |
| Hydroxyzine | 15 | $106 | $7 |
| Lithium Carbonate | 22 | $99 | $4 |
| Duloxetine | 11 | $84 | $8 |
| Lorazepam | 19 | $61 | $3 |
| Lamotrigine | 13 | $46 | $4 |
| Ropinirole | 11 | $32 | $3 |
Year by year
| 2024 | 938 | 45 | 0% (0) | 16% | $704,935 |
| 2023 | 925 | 54 | 0% (0) | 12% | $590,838 |
| 2022 | 966 | 74 | 0% (0) | 17% | $600,003 |
| 2021 | 1,703 | 119 | 0% (0) | None | $702,683 |
| 2020 | 614 | 93 | 0% (0) | 11% | $235,024 |
| 2019 | 90 | 27 | 0% (0) | 13% | $14,225 |
| 2018 | 132 | 29 | 0% (0) | 11% | $6,784 |
| 2017 | 81 | 19 | 0% (0) | None | $6,891 |
| 2016 | 28 | None | 0% (0) | None | $5,235 |
| 2015 | 105 | 24 | 0% (0) | None | $4,756 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Invega Sustenna | 67 | $210,771 | $3,146 |
| Invega Trinza | 13 | $123,184 | $9,476 |
| Olanzapine | 107 | $5,151 | $48 |
| Clozapine | 71 | $4,749 | $67 |
| Divalproex Sodium Er | 73 | $3,173 | $43 |
| Asenapine Maleate | 11 | $2,731 | $248 |
| Aripiprazole | 25 | $2,403 | $96 |
| Fluphenazine | 18 | $1,982 | $110 |
| Quetiapine | 25 | $1,053 | $42 |
| Hydroxyzine | 18 | $613 | $34 |
| Gabapentin | 43 | $604 | $14 |
| Trazodone | 44 | $542 | $12 |
| Prazosin | 25 | $485 | $19 |
| Risperidone | 47 | $458 | $10 |
| Benztropine Mesylate | 31 | $393 | $13 |
| Mirtazapine | 17 | $377 | $22 |
| Propranolol | 14 | $260 | $19 |
| Lithium Carbonate Er | 13 | $247 | $19 |
| Sertraline | 33 | $227 | $7 |
| Lamotrigine | 23 | $149 | $6 |
| Divalproex | 12 | $97 | $8 |
| Fluoxetine | 22 | $95 | $4 |
| Escitalopram | 19 | $83 | $4 |
| Topiramate | 13 | $61 | $5 |
| Lorazepam | 13 | $34 | $3 |
| Trihexyphenidyl | 12 | $22 | $2 |
2022: 30 drugs
| Invega Sustenna | 81 | $231,617 | $2,859 |
| Invega Trinza | 19 | $164,667 | $8,667 |
| Ingrezza | 15 | $112,680 | $7,512 |
| Vraylar | 21 | $29,939 | $1,426 |
| Olanzapine | 111 | $5,686 | $51 |
| Paliperidone Er | 12 | $5,259 | $438 |
| Clozapine | 61 | $4,692 | $77 |
| Varenicline | 11 | $3,793 | $345 |
| Asenapine Maleate | 12 | $2,685 | $224 |
| Divalproex Sodium Er | 64 | $1,980 | $31 |
| Hydroxyzine | 39 | $829 | $21 |
| Quetiapine | 31 | $566 | $18 |
| Aripiprazole | 19 | $526 | $28 |
| Gabapentin | 38 | $510 | $13 |
| Risperidone | 35 | $480 | $14 |
| Perphenazine | 13 | $317 | $24 |
| Prazosin | 18 | $256 | $14 |
| Lithium Carbonate Er | 15 | $242 | $16 |
| Trazodone | 52 | $241 | $5 |
| Lamotrigine | 20 | $191 | $10 |
| Escitalopram | 23 | $173 | $8 |
| Benztropine Mesylate | 31 | $154 | $5 |
| Mirtazapine | 13 | $143 | $11 |
| Fluoxetine | 26 | $131 | $5 |
| Propranolol | 12 | $119 | $10 |
| Trihexyphenidyl | 18 | $89 | $5 |
| Sertraline | 38 | $89 | $2 |
| Topiramate | 12 | $57 | $5 |
| Clonazepam | 11 | $51 | $5 |
| Lorazepam | 13 | $34 | $3 |
2021: 41 drugs
| Invega Trinza | 36 | $297,294 | $8,258 |
| Invega Sustenna | 90 | $238,066 | $2,645 |
| Latuda | 28 | $39,734 | $1,419 |
| Vraylar | 13 | $20,223 | $1,556 |
| Abilify | 11 | $18,625 | $1,693 |
| Prozac | 20 | $10,547 | $527 |
| Trintellix | 21 | $8,946 | $426 |
| Paliperidone Er | 21 | $8,353 | $398 |
| Divalproex Sodium Er | 125 | $5,378 | $43 |
| Clozapine | 55 | $4,398 | $80 |
| Fluphenazine | 12 | $4,225 | $352 |
| Olanzapine | 154 | $2,738 | $18 |
| Haloperidol | 33 | $1,716 | $52 |
| Aripiprazole | 47 | $1,630 | $35 |
| Mirtazapine | 43 | $1,535 | $36 |
| Benztropine Mesylate | 109 | $905 | $8 |
| Venlafaxine Hcl Er | 12 | $821 | $68 |
| Quetiapine | 94 | $815 | $9 |
| Bupropion Xl | 26 | $703 | $27 |
| Risperidone | 47 | $654 | $14 |
| Gabapentin | 48 | $579 | $12 |
| Lithium Carbonate Er | 27 | $553 | $20 |
| Trazodone | 87 | $405 | $5 |
| Quetiapine Fumarate Er | 18 | $404 | $22 |
| Escitalopram | 47 | $377 | $8 |
| Lamotrigine | 28 | $350 | $12 |
| Prazosin | 32 | $332 | $10 |
| Perphenazine | 12 | $305 | $25 |
| Hydroxyzine | 47 | $285 | $6 |
| Duloxetine | 33 | $231 | $7 |
| Fluoxetine | 28 | $213 | $8 |
| Carbamazepine | 12 | $191 | $16 |
| Lithium Carbonate | 21 | $173 | $8 |
| Clonazepam | 19 | $164 | $9 |
| Sertraline | 40 | $147 | $4 |
| Buspirone | 18 | $113 | $6 |
| Citalopram Hbr | 16 | $81 | $5 |
| Trihexyphenidyl | 20 | $66 | $3 |
| Topiramate | 13 | $61 | $5 |
| Propranolol | 11 | $60 | $5 |
| Lorazepam | 22 | $49 | $2 |
2020: 20 drugs
| Invega Trinza | 20 | $148,222 | $7,411 |
| Invega Sustenna | 16 | $40,972 | $2,561 |
| Clozapine | 36 | $2,703 | $75 |
| Aripiprazole | 17 | $1,715 | $101 |
| Divalproex Sodium Er | 35 | $1,109 | $32 |
| Duloxetine | 22 | $875 | $40 |
| Olanzapine | 61 | $783 | $13 |
| Haloperidol | 15 | $614 | $41 |
| Benztropine Mesylate | 41 | $421 | $10 |
| Bupropion Xl | 11 | $384 | $35 |
| Gabapentin | 15 | $248 | $17 |
| Risperidone | 23 | $246 | $11 |
| Lamotrigine | 20 | $180 | $9 |
| Quetiapine | 26 | $151 | $6 |
| Clonazepam | 13 | $125 | $10 |
| Lithium Carbonate | 22 | $120 | $5 |
| Trazodone | 22 | $89 | $4 |
| Sertraline | 21 | $85 | $4 |
| Mirtazapine | 14 | $81 | $6 |
| Hydroxyzine | 12 | $75 | $6 |
2019: 1 drug
| Quetiapine | 11 | $137 | $12 |
2018: 1 drug
| Trazodone | 11 | $45 | $4 |
2017: 1 drug
| Quetiapine | 13 | $312 | $24 |
Money from drug and device companies
$2,764 in 2025
| 2025 | 10 | 87 | None | $2,764 |
| 2024 | 11 | 68 | None | $1,812 |
| 2023 | 11 | 71 | None | $3,691 |
| 2022 | 8 | 52 | None | $3,425 |
| 2021 | 6 | 33 | None | $1,088 |
| 2020 | 2 | 2 | None | $147 |
| 2019 | 2 | 23 | None | $564 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $654 | 13 payments
|
| Vanda Pharmaceuticals | Fanapt | $623 | 21 payments
|
| Alkermes | Aristada | $456 | 18 payments
|
| Axsome Therapeutics | Auvelity | $279 | 9 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $210 | 5 payments
|
| Neurocrine BioSciences | Ingrezza | $207 | 7 payments
|
See all 87 published payments
| Alkermes | Meals · 2025-12-17 | Aristada | $27 |
| Vanda Pharmaceuticals | Meals · 2025-12-16 | Fanapt | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-12-09 | Austedo Xr | $25 |
| Axsome Therapeutics | Education · 2025-12-08 | Auvelity | $61 |
| Vanda Pharmaceuticals | Meals · 2025-12-04 | Fanapt | $32 |
| Vanda Pharmaceuticals | Meals · 2025-12-03 | Fanapt | $121 |
| Neurocrine BioSciences | Meals · 2025-12-03 | Ingrezza | $26 |
| Axsome Therapeutics | Meals · 2025-12-02 | Auvelity | $56 |
| Alkermes | Meals · 2025-11-26 | Lybalvi | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-19 | Cobenfy | $28 |
| Alkermes | Meals · 2025-11-19 | Aristada | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-13 | Cobenfy | $123 |
| Axsome Therapeutics | Meals · 2025-11-06 | Auvelity | $25 |
| Vanda Pharmaceuticals | Meals · 2025-10-30 | Fanapt | $37 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-23 | Cobenfy | $25 |
| Alkermes | Meals · 2025-10-22 | Aristada | $30 |
| Neurocrine BioSciences | Meals · 2025-10-22 | Ingrezza | $33 |
| Alkermes | Meals · 2025-10-10 | Aristada | $32 |
| Axsome Therapeutics | Meals · 2025-10-09 | Auvelity | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-10-09 | Uzedy | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-30 | Cobenfy | $31 |
| Vanda Pharmaceuticals | Meals · 2025-09-25 | Fanapt | $32 |
| Alkermes | Meals · 2025-09-18 | Aristada | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-09-18 | Rexulti | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-10 | Cobenfy | $78 |
| Neurocrine BioSciences | Meals · 2025-09-10 | Ingrezza | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-09-10 | Austedo Xr | $35 |
| Abbvie | Meals · 2025-09-04 | Vraylar | $19 |
| Alkermes | Meals · 2025-09-02 | Lybalvi | $19 |
| Alkermes | Meals · 2025-09-02 | Lybalvi | $2 |
| Vanda Pharmaceuticals | Meals · 2025-08-28 | Fanapt | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-26 | Cobenfy | $19 |
| Alkermes | Meals · 2025-08-20 | Aristada | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-14 | Cobenfy | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-08-11 | Rexulti | $32 |
| Vanda Pharmaceuticals | Meals · 2025-07-22 | Fanapt | $25 |
| Axsome Therapeutics | Meals · 2025-07-22 | Auvelity | $27 |
| Vanda Pharmaceuticals | Meals · 2025-07-17 | Fanapt | $32 |
| Neurocrine BioSciences | Meals · 2025-07-16 | Ingrezza | $25 |
| Alkermes | Meals · 2025-07-10 | Aristada | $33 |
| Vanda Pharmaceuticals | Meals · 2025-07-08 | Fanapt | $28 |
| Alkermes | Meals · 2025-07-04 | Aristada | $25 |
| Teva Pharmaceuticals USA | Education · 2025-07-01 | None | $111 |
| Teva Pharmaceuticals USA | Meals · 2025-07-01 | Austedo Xr | $23 |
| Vanda Pharmaceuticals | Meals · 2025-06-24 | Fanapt | $28 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-24 | Caplyta | $10 |
| Vanda Pharmaceuticals | Meals · 2025-06-18 | Fanapt | $23 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-17 | Caplyta | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-06-13 | Rexulti | $22 |
| Abbvie | Meals · 2025-06-11 | Vraylar | $26 |
| Alkermes | Meals · 2025-06-04 | Aristada | $29 |
| Vanda Pharmaceuticals | Meals · 2025-06-04 | Fanapt | $26 |
| Vanda Pharmaceuticals | Meals · 2025-05-27 | Fanapt | $10 |
| Alkermes | Meals · 2025-05-14 | Lybalvi | $22 |
| Vanda Pharmaceuticals | Meals · 2025-05-13 | Fanapt | $9 |
| Axsome Therapeutics | Meals · 2025-05-13 | Auvelity | $30 |
| Vanda Pharmaceuticals | Meals · 2025-05-08 | Fanapt | $24 |
| Axsome Therapeutics | Meals · 2025-05-07 | Auvelity | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-05 | Cobenfy | $26 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-01 | Caplyta | $32 |
| Axsome Therapeutics | Meals · 2025-04-30 | Auvelity | $26 |
| Alkermes | Meals · 2025-04-25 | Aristada | $26 |
| Vanda Pharmaceuticals | Meals · 2025-04-22 | Fanapt | $33 |
| Abbvie | Meals · 2025-04-16 | Vraylar | $23 |
| Vanda Pharmaceuticals | Meals · 2025-04-09 | Fanapt | $23 |
| Neurocrine BioSciences | Meals · 2025-04-02 | Ingrezza | $25 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-28 | Caplyta | $12 |
| Alkermes | Meals · 2025-03-27 | Aristada | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-20 | Cobenfy | $98 |
| Vanda Pharmaceuticals | Meals · 2025-03-20 | Fanapt | $11 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-20 | Caplyta | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-12 | Cobenfy | $20 |
| Vanda Pharmaceuticals | Meals · 2025-03-10 | Fanapt | $24 |
| Neurocrine BioSciences | Meals · 2025-03-07 | Ingrezza | $35 |
| Alkermes | Meals · 2025-02-27 | Aristada | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-20 | Cobenfy | $133 |
| Alkermes | Meals · 2025-02-20 | Lybalvi | $30 |
| Vanda Pharmaceuticals | Meals · 2025-02-19 | Fanapt | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-13 | Cobenfy | $26 |
| Neurocrine BioSciences | Meals · 2025-02-12 | Ingrezza | $33 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-07 | Caplyta | $28 |
| Janssen Pharmaceuticals | Meals · 2025-01-31 | Invega Sustenna | $23 |
| Axsome Therapeutics | Meals · 2025-01-29 | Auvelity | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-22 | Cobenfy | $24 |
| Vanda Pharmaceuticals | Meals · 2025-01-17 | Fanapt | $34 |
| Alkermes | Meals · 2025-01-16 | Aristada | $28 |
| Abbvie | Meals · 2025-01-10 | Vraylar | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,812
| Alkermes | Aristada | $372 | 12 payments
|
| Teva Pharmaceuticals USA | Uzedy | $358 | 20 payments
|
| Lundbeck | Abilify Asimtufii | $213 | 10 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $205 | 5 payments
|
| Abbvie | Vraylar | $204 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $149 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $122 | 4 payments
|
| Indivior | Perseris | $93 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $44 | 2 payments
|
| Axsome Therapeutics | Auvelity | $27 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $26 | 1 payment
|
2023: $3,691
| Neurocrine Biosciences | Ingrezza | $2,298 | 14 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $349 | 17 payments
|
| Abbvie | Vraylar | $340 | 15 payments
|
| Indivior | Perseris | $181 | 7 payments
|
| Alkermes | Aristada | $159 | 7 payments
|
| BioXcel Therapeutics | Igalmi | $116 | 2 payments
|
| Janssen Pharmaceuticals | Spravato | $85 | 3 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $52 | 2 payments
|
| Bausch Health US | Aplenzin | $49 | 2 payments
|
| Neuronetics | Neurostar Tms Therapy System | $45 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $16 | 1 payment
|
2022: $3,425
| Biohaven Pharmaceutical Holding Company | None | $2,215 | 8 payments
|
| Teva Pharmaceuticals USA | Austedo | $314 | 6 payments
|
| Abbvie | Vraylar | $276 | 13 payments
|
| Neurocrine Biosciences | Ingrezza | $248 | 8 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $163 | 6 payments
|
| Sunovion Pharmaceuticals | Latuda | $162 | 9 payments
|
| Lundbeck | Rexulti | $29 | 1 payment
|
| Bausch Health US | Aplenzin | $17 | 1 payment
|
2021: $1,088
| AbbVie | Vraylar | $410 | 13 payments
|
| Neurocrine Biosciences | Ingrezza | $377 | 8 payments
|
| Alkermes | Aristada | $115 | 5 payments
|
| Teva Pharmaceuticals USA | Austedo | $89 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $57 | 3 payments
|
| Lundbeck | Abilify Maintena | $40 | 2 payments
|
2020: $147
| Otsuka America Pharmaceutical | Abilify Maintena | $125 | 1 payment
|
| Alkermes | Aristada | $22 | 1 payment
|
2019: $564
| Alkermes | Aristada | $433 | 15 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $131 | 8 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Vanda Pharmaceuticals Inc. · A Study To Investigate the Efficacy of Tradipitant in Subjects Affected By Motion Sickness · 2024 | Their institution | $535,941 |
| Vanda Pharmaceuticals Inc. · An Open Label Study To Investigate the Safety and Efficacy of Tradipitant in Participants Affected By Motion Sickness · 2024 | Their institution | $441,076 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Vqw-765 Vs. Placebo in Performance Anxiety · 2022 | Their institution | $259,453 |
| Vanda Pharmaceuticals Inc. · Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected By Motion Sickness · 2025 | Their institution | $221,565 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · A 6-Week, Multi-Centre, Randomised, Double-Blind (Participant and Investigator), Placebo-Controlled, Dose-Finding Trial To Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral Bi 1569912 in Patients With Major Depressive Disorder · 2025 | Their institution | $208,142 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Vqw-765 Vs. Placebo in Performance Anxiety · 2021 | Their institution | $191,691 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $131,645 |
| Vanda Pharmaceuticals Inc. · A Study To Investigate the Efficacy of Tradipitant in Subjects Affected By Motion Sickness · 2023 | Their institution | $126,068 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2023 | Their institution | $120,891 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate-To-Severe Anhedonia An · 2025 | Their institution | $92,484 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $66,689 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2023 | Their institution | $60,604 |
| Janssen Research & Development, LLC · A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study To Evaluate Efficacy and Safety and the Maintenance of Effect of 20-Mg Seltorexant As Adjunctive Therapy To Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms · 2025 | Their institution | $54,075 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2024 | Their institution | $48,689 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $45,722 |
| Siemens Medical Solutions USA, Inc. · Advia Centaur Xp Analyzer · 2021 | Their institution | $43,885 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate-To-Severe Anhedonia An · 2024 | Their institution | $40,606 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2023 | Their institution | $32,998 |
| Neurocrine BioSciences Inc. · A Phase 4, Single-Arm, Open-Label Study To Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia · 2024 | Their institution | $31,923 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2024 | Their institution | $30,285 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Proof-of-Concept Study To Evaluate the Efficacy, Safety, and Tolerability of Jnj-89495120 As Monotherapy in Adult Participants With Major Depressive Disorder (Mdd) · 2025 | Their institution | $28,510 |
| Janssen Research & Development, LLC · A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study To Evaluate Efficacy and Safety and the Maintenance of Effect of 20-Mg Seltorexant As Adjunctive Therapy To Antidepressants in Adult and Elderly Patients With Major Depressive Diso · 2025 | Their institution | $24,700 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Vqw-765 Vs. Placebo in Performance Anxiety · 2023 | Their institution | $24,543 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $22,770 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (Asd) and Sleep Disturbances · 2022 | Their institution | $21,022 |
| Vanda Pharmaceuticals Inc. · An Open Label Study To Investigate the Safety and Efficacy of Tradipitant in Participants Affected By Motion Sickness · 2023 | Their institution | $18,850 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $15,657 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2023 | Their institution | $15,546 |
| Vanda Pharmaceuticals Inc. · Evaluation of Efficacy and Safety of Milsaperidone As Adjunctive Therapy in Patients With Major Depressive Disorder · 2025 | Their institution | $13,450 |
| Vanda Pharmaceuticals Inc. · Study To Evaluate the Efficacy and Safety of Vqw-765 for the on-Demand Treatment of Social Anxiety Disorder · 2025 | Their institution | $11,755 |
| ABBVIE INC. · A Study of Oral Atogepant Tablets To Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 To 17 Years · 2025 | Their institution | $11,552 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2025 | Their institution | $10,468 |
| ABBVIE INC. · A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 To 17 Years of Age) With Bipolar I Disorder · 2024 | Their institution | $9,500 |
| ABBVIE INC. · A Study To Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2025 | Their institution | $9,202 |
| ABBVIE INC. · M21-201 - A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2025 | Their institution | $7,485 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2025 | Their institution | $7,144 |
| ABBVIE INC. · M21-199 - Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2025 | Their institution | $6,559 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $6,390 |
| Boehringer Ingelheim International GmbH · A 6-Week, Multi-Centre, Randomised, Double-Blind (Participant and Investigator), Placebo-Controlled, Dose-Finding Trial To Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral Bi 1569912 in Patients With Major Depressive Disorder · 2025 | Their institution | $5,200 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects Oftasimelteonin Individuals With Autism Spectrum Disorder (Asd) and Sleep Disturbances · 2025 | Their institution | $5,048 |
| Siemens Medical Solutions USA, Inc. · Amh Apparently Healthy · 2022 | Their institution | $4,500 |
| ABBVIE INC. · A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 To 17 Years of Age) With Bipolar I Disorder · 2025 | Their institution | $4,400 |
| Boehringer Ingelheim International GmbH · Phase II Dose Finding Trial in Monotherapy for Mdd · 2024 | Their institution | $3,776 |
| ABBVIE INC. · A Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety of Atogepant in Pediatric Subjects 6 To 17 Years of Age With Episodic Migraine · 2024 | Their institution | $3,742 |
| Boehringer Ingelheim RCV GmbH & Co KG · Connex 1 · 2023 | Their institution | $2,013 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $1,440 |
| ABBVIE INC. · 3110-305-002 Ph3 Pivotal Peds Post Approval - Pmr (M21-265) · 2024 | Their institution | $1,440 |
| ABBVIE INC. · A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age. · 2025 | Their institution | $1,200 |
| ABBVIE INC. · M21-201 Atogepant Ph3 Em Peds (3101-307-002) · 2024 | Their institution | $1,200 |
| ABBVIE INC. · A 6-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 To 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder · 2025 | Their institution | $1,100 |
| ABBVIE INC. · 3112-301-001 Bipolar Depression Pediatric Safety and Efficacy (M21-211) · 2024 | Their institution | $956 |
| ABBVIE INC. · A Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety and Tolerability of Atogepant in Pediatric Subjects 6 To 17 Years of Age With Migraine · 2025 | Their institution | $600 |
| ABBVIE INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2024 | Their institution | $462 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-3 · 2024 | Their institution | $413 |
| Boehringer Ingelheim RCV GmbH & Co KG · Connex-3 · 2024 | Their institution | $390 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $263 |
| ABBVIE INC. · A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 To 17 Years of Age · 2025 | Their institution | $234 |
Professional record
- NPI
- 1134360647
- Licence
- CA A151871, TN 55981, TN MDST755California A151871: Current · expires 2026-12-31Tennessee 55981: LicensedTennessee 755: Licensed
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 2516 Samaritan Dr Ste B, San Jose, CA, 95124
- NPI first listed
- 2009-03-12
- NPI last updated
- 2025-10-22
- NPI record certified
- 2025-10-22
This is when the NPI record was last certified, not a medical board exam.